P53-based therapeutics for head and neck squamous cell carcinoma

Oral Oncology

Volumn 49, Issue 8, 2013, Pages 733-737

  Tassone, Patrick ^a   Old, Matthew ^a,b   Teknos, Theodoros N ^a,b   Pan, Quintin ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti cancer therapeutics; Gene therapy; Head and neck cancer; Human papillomavirus; Oral cancer; Tumor suppressor gene p53

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FLUOROURACIL; LONTUCIREV; METHOTREXATE; MICRORNA 200C; MICRORNA 34A; PROTEIN P53; RECOMBINANT ADENOVIRUS P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; DISEASES; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE THERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTION SITE PAIN; LEUKOCYTOSIS; LEUKOPLAKIA; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR VOLUME; WILD TYPE;

ANTI-CANCER THERAPEUTICS; GENE THERAPY; HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS; ORAL CANCER; P53; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880063586     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.03.447     Document Type: Review

References (41)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. M.L. Gillison, and D.R. Lowy A causal role for human papillomavirus in head and neck cancer Lancet 363 9420 2004 1488 1489
3. P. Sinha, H.L. Logan, and W.M. Mendenhall Human papillomavirus, smoking, and head and neck cancer Am J Otolaryngol 33 1 2012 130 136
4. K.D. Somers, M.A. Merrick, M.E. Lopez, L.S. Incognito, G.L. Schechter, and G. Casey Frequent p53 mutations in head and neck cancer Cancer Res 52 21 1992 5997 6000
5. D.P. Lane, and L.V. Crawford T antigen is bound to a host protein in SV40-transformed cells Nature 278 5701 1979 261 263
6. J.M. Nigro, S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, and K. Cleary Mutations in the p53 gene occur in diverse human tumour types Nature 342 6250 1989 705 708
7. V.E. Velculescu, and W.S. El-Deiry Biological and clinical importance of the p53 tumor suppressor gene Clin Chem 42 6 Pt 1 1996 858 868
8. M. Gasco, and T. Crook The p53 network in head and neck cancer Oral Oncol 39 3 2003 222 231
9. M. Olivier, R. Eeles, M. Hollstein, M.A. Khan, C.C. Harris, and P. Hainaut The IARC TP53 database: new online mutation analysis and recommendations to users Hum Mutat 19 6 2002 607 614
10. K. Ohnishi, I. Ota, A. Takahashi, K. Yane, H. Matsumoto, and T. Ohnishi Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck Apoptosis 7 4 2002 367 372
11. M.L. Poeta, J. Manola, M.A. Goldwasser, A. Forastiere, N. Benoit, and J.A. Califano TP53 mutations and survival in squamous-cell carcinoma of the head and neck N Engl J Med 357 25 2007 2552 2561
12. T.J. Liu, A.K. El-Naggar, T.J. McDonnell, K.D. Steck, M. Wang, and D.L. Taylor Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck Cancer Res 55 14 1995 3117 3122
13. K.F. Pirollo, Z. Hao, A. Rait, Y.J. Jang, W.E. Fee Jr., and P. Ryan P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy Oncogene 14 14 1997 1735 1746
14. J. Nemunaitis, and J. Nemunaitis Head and neck cancer: response to p53-based therapeutics Head Neck 33 1 2011 131 134
15. G.L. Clayman, A.K. El-Naggar, S.M. Lippman, Y.C. Henderson, M. Frederick, and J.A. Merritt Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma J Clin Oncol 16 6 1998 2221 2232
16. G.H. Yoo, J. Moon, M. Leblanc, F. Lonardo, S. Urba, and H. Kim A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group Arch Otolaryngol Head Neck Surg 135 9 2009 869 874
17. S. Zhang, Y. Li, L. Li, Y. Zhang, N. Gao, and Z. Zhang Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia J Oral Maxillofac Surg 67 5 2009 1074 1082
18. Y. Li, L.J. Li, S.T. Zhang, L.J. Wang, Z. Zhang, and N. Gao In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia Clin Cancer Res 15 21 2009 6724 6731
19. J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, and E. Vokes Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 19 2 2001 289 298
20. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, and M. Muna An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 264 1996 373 376
21. H. Heise, A. Sampson-Johannes, A. Williams, F. McCormack, D.D. Von Hoff, and D.H. Kirn Onyx-015, an E1B gene-attenuated adenovirus, causes tumour specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 3 1997 639 645
22. I. Ganly, D. Kirn, G. Eckhardt, G.I. Rodriguez, D.S. Soutar, and R. Otto A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 3 2000 798 806
23. J. Nemunaitis, C. Cunningham, A. Buchanan, A. Blackburn, G. Edelman, and P. Maples Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity Gene Ther 8 10 2001 746 759
24. J.P. Lamont, J. Nemunaitis, J.A. Kuhn, S.A. Landers, and T.M. McCarty A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience) Ann Surg Oncol 7 8 2000 588 592
25. F.R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I.F. Tannock, and L. Romel A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 6 8 2000 879 885
26. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, and P. Chumakov Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat Med 8 3 2002 282 288
27. Y. Li, Y. Mao, P.W. Brandt-Rauf, A.C. Williams, and R.L. Fine Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway Mol Cancer Ther 4 6 2005 901 909
28. J.L. Roh, S.K. Kang, I. Minn, J.A. Califano, D. Sidransky, and W.M. Koch P53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma Oral Oncol 47 1 2011 8 15
29. B.A. Foster, H.A. Coffey, M.J. Morin, and F. Rastinejad Pharmacological rescue of mutant p53 conformation and function Science 286 5449 1999 2507 2510
30. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett 420 1 1997 25 27
31. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, and H. Hilton Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc Natl Acad Sci USA 103 6 2006 1888 1893
32. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 5659 2004 844 848
33. N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L.G. Verhoef, and M. Masucci Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nat Med 10 12 2004 1321 1328
34. J.L. Roh, J.H. Ko, S.J. Moon, C.H. Ryu, J.Y. Choi, and W.M. Koch The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer Cancer Lett 325 1 2012 35 41
35. J.M. Huibregtse, M. Scheffner, and P.M. Howley A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18 EMBO J 10 1991 4129 4135
36. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
37. A.L. Talis, J.M. Huibregtse, and P.M. Howley The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells J Biol Chem 273 1998 6439 6445
38. H. Zimmermann, R. Degenkolbe, H.U. Bernard, and M.J. O'Connor The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator BP/p300 J Virol 73 1999 6209 6219
39. D. Patel, S.M. Huang, L.A. Baglia, and D.J. McCance The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300 EMBO J 18 1999 5061 5072
40. M.C. Thomas, and C.M. Chiang E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation Mol Cell 17 2005 251 264
41. Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, et al. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 2013. doi: http://dx.doi.org/10.1038/onc.2013.25 [Epub ahead of print].